GlobeNewswire: Cynata Therapeutics Limited Contains the last 10 of 46 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T14:52:57ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/06/30/2255699/0/en/Ethics-Approval-for-Cynata-s-Clinical-Trial-in-Diabetic-Foot-Ulcers.html?f=22&fvtc=4&fvtv=35124Ethics Approval for Cynata’s Clinical Trial in Diabetic Foot Ulcers2021-06-30T12:56:56Z<![CDATA[Key highlights]]>https://www.globenewswire.com/news-release/2021/06/03/2241276/0/en/Cynata-signs-Licence-Agreement-with-TekCyte-to-advance-Clinical-Trial-in-Diabetic-Foot-Ulcers.html?f=22&fvtc=4&fvtv=35124Cynata signs Licence Agreement with TekCyte to advance Clinical Trial in Diabetic Foot Ulcers 2021-06-03T12:00:00Z<![CDATA[MELBOURNE, Australia, June 03, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a worldwide exclusive licence agreement with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. Cynata has also secured an option to purchase the relevant technology outright.]]>https://www.globenewswire.com/news-release/2021/05/24/2234644/0/en/First-Patient-Enrolled-in-Cynata-s-MEND-Clinical-Trial.html?f=22&fvtc=4&fvtv=35124First Patient Enrolled in Cynata’s MEND Clinical Trial2021-05-24T12:00:00Z<![CDATA[MELBOURNE, Australia, May 24, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that the first patient has been enrolled in its MEND (MEseNchymal coviD-19) clinical trial. Originally designed to recruit COVID-19 patients admitted to intensive care with respiratory distress the study was expanded in late March this year to include patients in intensive care with respiratory failure resulting from causes beyond COVID-19.]]>https://www.globenewswire.com/news-release/2021/03/29/2200737/0/en/Cynata-Expands-MEND-clinical-trial-in-COVID-19-and-Respiratory-Failure.html?f=22&fvtc=4&fvtv=35124Cynata Expands MEND clinical trial in COVID-19 and Respiratory Failure2021-03-29T12:00:00Z<![CDATA[MELBOURNE, Australia, March 29, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received ethics committee approval to expand recruitment criteria in its active MEND (MEseNchymal coviD-19) clinical trial.]]>https://www.globenewswire.com/news-release/2021/03/02/2185264/0/en/New-Preclinical-Study-to-Investigate-the-High-Potency-of-Cymerus-MSCs.html?f=22&fvtc=4&fvtv=35124New Preclinical Study to Investigate the High Potency of Cymerus™ MSCs2021-03-02T13:00:00Z<![CDATA[MELBOURNE, Australia, March 02, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the initiation of a new study to investigate in a pre-clinical model of lung disease the potential molecular mechanisms involved in the observed high potency of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs).]]>https://www.globenewswire.com/news-release/2021/03/01/2184226/0/en/Cynata-Advances-Planned-Clinical-Trial-in-Diabetic-Foot-Ulcers-in-MoU-With-TekCyte.html?f=22&fvtc=4&fvtv=35124Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte2021-03-01T13:00:00Z<![CDATA[MELBOURNE, Australia, March 01, 2021 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced the execution of a Memorandum of Understanding with TekCyte Pty Ltd (TekCyte) in respect of TekCyte’s wound dressing technology. TekCyte has developed proprietary surface modification technologies to produce polymer-coated dressings for the delivery of mesenchymal stem cells (MSCs) to wounds. The MoU anticipates the parties negotiating and entering into a licence agreement for the use of TekCyte’s technologies in the commercial development of Cynata’s MSC product for diabetic foot ulcers (DFU).]]>https://www.globenewswire.com/news-release/2020/12/11/2143738/0/en/Cynata-Secures-15m-Placement-Led-By-10m-from-Healthcare-Investor-BioScience-Managers-to-Expand-Development-Pipeline.html?f=22&fvtc=4&fvtv=35124Cynata Secures $15m Placement Led By $10m from Healthcare Investor BioScience Managers to Expand Development Pipeline2020-12-11T13:00:00Z<![CDATA[MELBOURNE, Australia, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce a successful $15 million placement (“Placement”), led by a $10m investment from experienced healthcare investor BioScience Managers through the BioScience Managers Translation Fund I (BMTFI). BMTFI has a mandate to invest in Australian based innovative healthcare technology and this investment will allow Cynata to significantly expand its clinical development pipeline and scale their operations in Australia. The Placement is being undertaken at an offer price of $0.70 for each new share and will be followed by a 1 for 15 non-renounceable entitlement offer at the same offer price as the Placement.]]>https://www.globenewswire.com/news-release/2020/11/11/2124717/0/en/Phase-3-Osteoarthritis-Clinical-Trial-Commences.html?f=22&fvtc=4&fvtv=35124Phase 3 Osteoarthritis Clinical Trial Commences2020-11-11T13:00:00Z<![CDATA[MELBOURNE, Australia, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the Phase 3 SCUlpTOR (“Stem Cells as a symptom- and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis”) Trial of CYP-004, Cynata’s Cymerus™ mesenchymal stem cell (MSC) product for osteoarthritis, has now commenced.]]>https://www.globenewswire.com/news-release/2020/09/08/2090070/0/en/Cymerus-MSCs-Demonstrate-Efficacy-in-Preclinical-Lung-Disease-Study.html?f=22&fvtc=4&fvtv=35124Cymerus MSCs Demonstrate Efficacy in Preclinical Lung Disease Study2020-09-08T12:05:00Z<![CDATA[MELBOURNE, Australia, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced positive efficacy data from a study of its induced pluripotent stem cell (iPSC)-derived Cymerus™ mesenchymal stem cells (MSCs) in a preclinical rodent model of idiopathic pulmonary fibrosis (IPF).]]>https://www.globenewswire.com/news-release/2020/08/24/2082577/0/en/Patient-Enrolment-Opens-in-COVID-19-Clinical-Trial.html?f=22&fvtc=4&fvtv=35124Patient Enrolment Opens in COVID-19 Clinical Trial2020-08-24T12:05:00Z<![CDATA[MELBOURNE, Australia, Aug. 24, 2020 (GLOBE NEWSWIRE) -- Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that the MEND (MEseNchymal coviD-19) Trial is now open for patient enrolment. Following ethics committee approval (as announced on 8 May 2020), this important step represents the formal commencement of this clinical trial. The MEND Trial will investigate early efficacy of Cynata’s proprietary Cymerus™ mesenchymal stem cells (MSCs) in adults admitted to intensive care with COVID-19.]]>